Brain (OUP) 'Under Review': What Each Status Means and When to Expect a Decision

Before the paper reaches external reviewers, one or more Brain Editorial Board members evaluate whether the neurology-significance warrants Brain's selective editorial slots. About 60 to 70 percent of submissions are rejected without peer review at this stage. A desk rejection most often means the Editorial Board concluded that the work lacks novelty, involves normal subjects (rather than disease-relevant cohorts), has serious scientific flaws, or lies outside the scope of the journal.

Brain occupies a unique position as the bridge between mechanistic neuroscience and clinical neurology; papers that fit only one side of that bridge are often returned with a suggestion to submit elsewhere.

The Brain editorial office confirms files are complete: manuscript with figures embedded, supplementary information separate, CONSORT checklist for clinical trials (required), reporting checklists where applicable (STROBE for observational studies, ARRIVE for animal work), cover letter directed to the editor, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, trial-registration documentation (required for clinical trials), and data-availability statement.

One or more Brain Editorial Board members read the paper and evaluate neurology-significance, novelty, disease-relevance (versus normal-subjects work), and scientific rigor. The 2 to 4 week initial editorial decision target reflects the Editorial Board model where senior academic editors handle desk screening directly.

In parallel with the primary Editorial Board member's read, ambiguous-fit papers are discussed across the Brain Editorial Board where peer members with adjacent subspecialty expertise weigh in on whether the paper would fit better at Brain or at sister neurology journals. This Editorial-Board discussion runs alongside the desk-screen and adds 3 to 7 days to the timeline that is invisible to the author in the portal.

Papers that pass the Editorial Board screen are assigned to a handling editor (a Brain Editorial Board member with the closest subspecialty expertise). The handling editor identifies and invites external reviewers with topic-matched expertise.

Brain handling editors typically invite 2 to 3 external reviewers. The recruitment window can take 7 to 14 days because reviewers with topic-matched neurology subspecialty expertise (especially across the mechanistic-clinical bridge) are scarce.

Once reviewers agree to review, the typical Brain peer-review cycle lasts 4 to 8 weeks per reviewer. Reviewers are asked to evaluate neurology-significance, mechanistic-clinical bridge framing, scientific rigor, and reproducibility. Reviewer reports for Brain tend to be thorough; 2500 to 5000 word reports are typical given Brain's high-stakes editorial position in neurology.

After reports return, the handling editor synthesizes them and presents the case to the Editorial Board for final decision. The 6 to 10 week full peer-review window applies to papers that reach external peer review.

• Rejection within 1 to 7 days: Administrative issue or immediate scope mismatch.

• Rejection within 14 to 28 days: Editorial Board desk rejection per the 2 to 4 week target.

• Still Under Review after 4 weeks: Strong signal. Paper passed the Editorial Board filter.

• Still Under Review after 12 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the ScholarOne portal is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from Brain authors during the active editorial window. The honest answer: no, 6 weeks at Under Review puts you in the normal middle of Brain's 4 to 6 week median to first decision distribution plus 6 to 10 week full peer-review window.

Reports may already be in editorial synthesis with the handling editor preparing the recommendation for the Editorial Board. Most reviewer-driven delays come from reviewer-recruitment timing rather than slow reviews because Brain recruits topic-matched neurology subspecialty reviewers (especially across the mechanistic-clinical bridge) who are scarce.

If the portal still says Under Review at the 10-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the handling editor granted it. This is normal practice at Brain.

What you should NOT do during the 6-to-10-week window is email the editorial office. Brain handling editors are working academic neurologists managing 20+ active papers around their own research; an inquiry at 6 weeks adds friction without accelerating the timeline.

If your Brain paper is rejected after review, the natural cascade depends on what the reviewers and Editorial Board cited:

Brain Communications is the natural OUP open-access cascade for neurology papers where the priority bar of Brain flagship is not met but the rigor is high. OUP supports manuscript-transfer with reviewer reports preserved.

Annals of Neurology is the American Neurological Association cascade for clinical-neurology research.

Nature Neuroscience is the external Springer Nature cascade for top-tier mechanistic neuroscience. The Nature Neuroscience Manuscript Tracking System at mts-nn.nature.com handles submission; nn@nature.com handles publisher-level inquiries.

Neuron is the external Cell Press cascade for top-tier neuroscience. Cell Press uses Editorial Manager at Editorial Manager submission portal; editorial contact neuron@cell.com.

Lancet Neurology is the Lancet specialty cascade for top-tier clinical-neurology global-impact research. The Lancet uses Editorial Manager at Editorial Manager submission portal; editorial contact editorial@lancet.com.

JAMA Neurology is the AMA neurology specialty cascade. JAMA Network uses ScholarOne at ScholarOne submission portal; editorial contact jamaneurology@jamanetwork.org.

OUP asks reviewers at Brain to evaluate four things specifically. The table below maps each to actionable preparation.

In our pre-submission work with Brain-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the desk screen.

Normal-subjects-only framing flagged at Editorial Board screen. When the Brain submission involves only normal subjects without disease translation, Editorial Board desk rejection within 2 to 4 weeks is common (per Brain's explicit desk-rejection criteria). The strongest manuscripts frame the abstract, introduction, and first results figure around the disease-relevant mechanism, not only the healthy-control observation.

In practice, the status often moves quickly from Submitted to Under Review and then to a decision when this bridge is missing because the Editorial Board can judge the fit before recruiting external reviewers.

Check whether your Brain disease-relevance framing is clear →

One-sided bridge framing flagged at desk screen. When the Brain introduction frames the work as purely mechanistic without clinical relevance, or purely clinical without mechanistic insight, Editorial Board return with a suggestion to submit elsewhere is common. We see this most often when the title and abstract promise a disease insight but the methods, cohort definition, imaging endpoint, or animal-model rationale cannot carry that claim.

The stronger version makes the mechanistic-clinical bridge explicit in the abstract conclusion, then preserves that logic in the figure sequence and discussion limitations.

Check your Brain mechanism-to-clinic bridge →

Brain Communications cascade offers from Editorial Board. When the Brain Editorial Board concludes the work is rigorous but the novelty or priority bar of Brain flagship is not met, transfer offers to Brain Communications are common. That cascade is usually a fit signal, not just a soft rejection, especially when the methods are solid but the clinical consequence, disease-relevance, or cross-subfield novelty is not broad enough for Brain.

Authors should read the decision letter for whether the concern is fixable by reframing the abstract and discussion or structural because the study population, controls, or endpoint package cannot support the flagship claim.

Check whether your Brain paper fits Brain or Brain Communications →

We have reviewed 50+ manuscripts targeting Brain, Brain Communications, Nature Neuroscience, Neuron, and Lancet Neurology. This guide tells you what Brain editors look for in the status window, while the review tells you whether your paper passes the same disease-relevance, figure-logic, methods-documentation, and mechanistic-clinical bridge checks before the Editorial Board or external reviewers see it. Full Manusights reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

In our pre-submission review work across neurology and neuroscience targets, Brain-bound drafts most often failed because the disease-relevance claim was not visible early enough in the abstract, first figure, or methods rationale. We see this as a recurring failure pattern rather than a status-timing problem. Source limitation: official guidance explains Brain's Editorial Board screen and review windows, but it cannot diagnose whether your specific manuscript has enough mechanistic-clinical bridge evidence to survive that screen.

Use this guide when you need to separate normal Brain status silence from a true follow-up moment before you submit, withdraw, or prepare a cascade plan.

This page was created from OUP's public Brain general instructions at Oxford Academic author instructions, Brain editorial documentation (2 to 4 week initial editorial decision target, 6 to 10 week full peer-review window, 10 to 15 percent acceptance, Editorial Board desk-rejection criteria including lack of novelty, involvement of normal subjects, serious scientific flaws, or work outside scope), SciRev community-reported transit data on Brain, and Manusights pre-submission review experience with Brain-targeted manuscripts.

For the neurology landscape beyond Brain, see Brain Communications (OUP open-access cascade), Annals of Neurology (ANA clinical-neurology), Nature Neuroscience (Springer Nature mechanistic neuroscience), Neuron (Cell Press neuroscience), Lancet Neurology (Lancet specialty clinical neurology), and JAMA Neurology (AMA neurology specialty).

The choice across these titles depends on whether the central contribution is mechanistic-to-clinical neurology bridge (Brain), OUP open-access neurology (Brain Communications), ANA clinical-neurology (Annals of Neurology), top-tier mechanistic (Nature Neuroscience, Neuron), top-tier global-clinical (Lancet Neurology), or AMA neurology (JAMA Neurology).

Reviewers at Brain typically draw from one mechanistic-neuroscience specialist and one clinical-neurology specialist (matched to the mechanistic-clinical bridge framing). Editors screen and triage manuscripts before any external reviewer sees them, and preparing a response template that addresses both mechanistic and clinical reviewer perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Brain mechanistic-clinical-bridge bar before submission, our Brain pre-submission diagnostic flags the framing and disease-relevance weaknesses most likely to surface in reviewer reports.